GC
GSK icon

Guggenheim Capital’s GSK GSK Stock Holding History

Guggenheim Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
4,019
-1,572
-28% -$83.1K ﹤0.01% 1636
2026
Q1 		$309K Sell
5,591
-921
-14% -$49.9K ﹤0.01% 1373
2025
Q4 		$319K Sell
6,512
-1,991
-23% -$92.9K ﹤0.01% 1495
2025
Q3 		$367K Sell
8,503
-983
-10% -$38.4K ﹤0.01% 1320
2025
Q2 		$364K Sell
9,486
-3,535
-27% -$135K ﹤0.01% 1327
2025
Q1 		$504K Sell
13,021
-2,032
-13% -$74.4K ﹤0.01% 1196
2024
Q4 		$509K Buy
15,053
+881
+6% +$31.7K ﹤0.01% 1260
2024
Q3 		$579K Sell
14,172
-9,718
-41% -$398K ﹤0.01% 1346
2024
Q2 		$920K Buy
23,890
+3,758
+19% +$158K 0.01% 1170
2024
Q1 		$863K Sell
20,132
-799
-4% -$33K 0.01% 1255
2023
Q4 		$776K Buy
20,931
+1,176
+6% +$42.2K 0.01% 1275
2023
Q3 		$716K Sell
19,755
-5,481
-22% -$195K 0.01% 1256
2023
Q2 		$899K Sell
25,236
-3,942
-14% -$141K 0.01% 1217
2023
Q1 		$1.04M Buy
29,178
+2,108
+8% +$73.7K 0.01% 1162
2022
Q4 		$951K Sell
27,070
-1,251
-4% -$41.7K 0.01% 1183
2022
Q3 		$833K Sell
28,321
-1,986
-7% -$75.3K 0.01% 1230
2022
Q2 		$1.65M Sell
30,307
-11,589
-28% -$640K 0.01% 977
2022
Q1 		$2.28M Sell
41,896
-8,518
-17% -$463K 0.01% 950
2021
Q4 		$2.78M Buy
50,414
+5,368
+12% +$279K 0.01% 905
2021
Q3 		$2.15M Buy
45,046
+2,949
+7% +$148K 0.01% 1016
2021
Q2 		$2.1M Buy
42,097
+2,327
+6% +$112K 0.01% 1068
2021
Q1 		$1.77M Sell
39,770
-3,488
-8% -$158K 0.01% 1095
2020
Q4 		$1.99M Buy
43,258
+96
+0.2% +$4.41K 0.01% 974
2020
Q3 		$2.03M Sell
43,162
-7,144
-14% -$358K 0.01% 886
2020
Q2 		$2.56M Buy
50,306
+1,304
+3% +$66.9K 0.02% 769
2020
Q1 		$2.32M Sell
49,002
-4,032
-8% -$215K 0.02% 721
2019
Q4 		$3.12M Sell
53,034
-198
-0.4% -$11K 0.02% 852
2019
Q3 		$2.84M Sell
53,232
-8,913
-14% -$459K 0.02% 862
2019
Q2 		$3.11M Sell
62,145
-20,061
-24% -$1.01M 0.03% 849
2019
Q1 		$4.29M Sell
82,206
-9,948
-11% -$497K 0.04% 699
2018
Q4 		$4.4M Sell
92,154
-28,925
-24% -$1.42M 0.04% 638
2018
Q3 		$6.08M Sell
121,079
-2,927
-2% -$149K 0.04% 613
2018
Q2 		$6.25M Buy
124,006
+724
+0.6% +$36.5K 0.04% 579
2018
Q1 		$6.02M Buy
123,282
+10,610
+9% +$494K 0.01% 905
2017
Q4 		$5M Sell
112,672
-55,767
-33% -$2.58M 0.01% 1038
2017
Q3 		$8.55M Buy
168,439
+17,905
+12% +$908K 0.02% 747
2017
Q2 		$8.11M Buy
150,534
+6,187
+4% +$330K 0.02% 750
2017
Q1 		$7.61M Sell
144,347
-6,051
-4% -$307K 0.02% 791
2016
Q4 		$7.24M Sell
150,398
-25,653
-15% -$1.27M 0.02% 804
2016
Q3 		$9.49M Sell
176,051
-6,273
-3% -$344K 0.03% 679
2016
Q2 		$9.88M Sell
182,324
-36,627
-17% -$1.93M 0.03% 666
2016
Q1 		$11.1M Sell
218,951
-7,476
-3% -$372K 0.04% 671
2015
Q4 		$11.4M Sell
226,427
-35,814
-14% -$1.83M 0.03% 704
2015
Q3 		$12.6M Buy
262,241
+88,719
+51% +$4.62M 0.04% 667
2015
Q2 		$9.04M Sell
173,522
-194,361
-53% -$10.9M 0.02% 878
2015
Q1 		$21.2M Buy
367,883
+138,263
+60% +$7.93M 0.05% 626
2014
Q4 		$12.3M Buy
229,620
+29,862
+15% +$1.67M 0.03% 755
2014
Q3 		$11.5M Sell
199,758
-147,873
-43% -$9.07M 0.03% 835
2014
Q2 		$23.2M Buy
347,631
+202,101
+139% +$13.7M 0.06% 589
2014
Q1 		$9.72M Sell
145,530
-162,084
-53% -$11M 0.03% 863
2013
Q4 		$20.5M Buy
307,614
+15,722
+5% +$1.02M 0.06% 565
2013
Q3 		$18.3M Buy
291,892
+15,649
+6% +$1.01M 0.07% 512
2013
Q2 		$17.3M Buy
+276,243
New +$17.5M 0.07% 423

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Guggenheim Capital's GSK Position: Q2 2026 in Review

Guggenheim Capital reduced its GSK (GSK) stake by 28% in Q2 2026, selling an estimated $83.1K and leaving 4,019 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Guggenheim Capital first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $23.2M in Q2 2014. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Guggenheim Capital held 4,019 shares of GSK worth $211K as of Q2 2026.
  • Guggenheim Capital sold 1,572 GSK shares in Q2 2026, an estimated $83.1K.
  • GSK made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1636 holding.
  • Guggenheim Capital first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • Guggenheim Capital's GSK position peaked at $23.2M in Q2 2014.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.